DYN101

DRUG2 trials

Sponsors

Dynacure

Conditions

Centronuclear Myopathy

Phase 1

Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies

TerminatedNCT04033159

DynacureCentronuclear Myopathy

Start: 2020-01-09End: 2022-06-22Updated: 2023-06-27

Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies

WithdrawnNCT04743557

DynacureCentronuclear Myopathy

Start: 2024-01-31End: 2025-11-30Updated: 2022-07-11

Related Papers

Clinical, histopathological, and biomarker characterization of XLMTM and ADCNM: Operational lessons, screening and baseline data of the Unite-CNM study

Journal of Neuromuscular Diseases2026-08-14

Liver function in X-linked myotubular myopathy and autosomal dominant centronuclear myopathy: Data of the unite-CNM study

Journal of Neuromuscular Diseases2025-04-24